TNM Classification of Malignant Tumours: Edition 8

Sold by John Wiley & Sons
1
Free sample

TNM Classification of Malignant Tumours eighth edition provides the latest, internationally agreed-upon standards to describe and categorize cancer stage.
  • Published in affiliation with the Union for International Cancer Control (UICC)
  • Arranged by anatomical region, this authoritative pocket sized guide contains many important updated organ-specific classifications
  • There are new classifications for p16 positive oropharyngeal carcinomas, carcinomas of the thymus, neuroendocrine tumours of the pancreas, and sarcomas
  • To facilitate the collection of stage data for cancer surveillance in low and middle income countries there are new sections on Essential TNM and Paediatric Cancer Stage
  • New colour presentation

Erratum


TNM Classification of Malignant Tumours, 8th edition is available as an app for iOS and Android. This Wiley app-book is developed by MedHand Mobile Libraries. Improve your performance with relevant, valid material which is accessed quickly and with minimal effort in the palm of your hand using MedHand's patented technology.

Click here to buy online or to find out more

Read more

About the author

James D. Brierley, BSc, MB, FRCP, FRCR, FRCPC
Professor, Department of Radiation Oncology, Princess Margaret Cancer Centre and the University of Toronto, Canada
Dr Brierley trained in Clinical Oncology in the UK and developed his interest in cancer staging and surveillance when moving to Canada and has been involved in cancer surveillance, locally, nationally and internationally. He is Co-Chair of the UICC TNM Prognostic Factors Project. He has co-edited the TNM Supplement 4th edition (Wiley 2012) and the UICC Manual of Clinical Oncology (Wiley 2015).

Mary K. Gospodarowicz MD, FRCPC, FRCR (Hon)
Medical Director, Princess Margaret Cancer Centre, University Health Network; Regional Vice-President of Cancer Care Ontario for Toronto South; Toronto, Ontario, Canada
Dr Gospodarowicz is the Past-President of UICC. She has a long-standing interest in cancer classification with an emphasis on staging and prognostic factors and she has been involved in the UICC TNM Project for many years. Her interests include the application of modern information and communication technologies in cancer control. Dr Gospodarowicz was coeditor of the 7th edition of the TNM Classification of Malignant Tumours (Wiley 2009) and editor of the 2nd and 3rd editions of the UICC Prognostic Factors in Cancer (Wiley 2001, 2006).

Christian Wittekind MD
Professor of Pathology, Chairman Institute of Pathology, University of Leipzig, Germany
Dr Wittekind been involved in cancer staging and tumour classifications for over 20 years. He is a member of the UICC TNM Core Committee, Head of the German Speaking TNM-Komittee, and personally responds to all the questions to the UICC TNM helpdesk. He was the coeditor of the 5th , 6th and 7th edition of the TNM classification of Malignant Tumours (Wiley 1997, 2002, 2009) editor of the 2nd, 3rd, and 4th edition of the TNM Supplement (Wiley 2001, 2003 and 2012) and editor of the 6th edition of the TNM Atlas (Wiley 2014).

Read more

Reviews

3.0
1 total
Loading...

Additional Information

Publisher
John Wiley & Sons
Read more
Published on
Nov 22, 2016
Read more
Pages
272
Read more
ISBN
9781119263562
Read more
Language
English
Read more
Genres
Medical / General
Medical / Oncology
Read more
Content Protection
This content is DRM protected.
Read more
Read Aloud
Available on Android devices
Read more

Reading information

Smartphones and Tablets

Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.

Laptops and Computers

You can read books purchased on Google Play using your computer's web browser.

eReaders and other devices

To read on e-ink devices like the Sony eReader or Barnes & Noble Nook, you'll need to download a file and transfer it to your device. Please follow the detailed Help center instructions to transfer the files to supported eReaders.
Paul Hermanek
M. K. Gospodarowicz, P. Hermanek, and D. E. Henson Attention to innovations in cancer treatment has tended to eclipse the importance of prognostic assessment. However, the recognition that prognostic factors often have a greater impact on outcome than available therapies and the proliferation of biochemical, molecular, and genetic markers have resulted in renewed interest in this field. The outcome in patients with cancer is determined by a combination of numerous factors. Presently, the most widely recognized are the extent of disease, histologic type of tumor, and treatment. It has been known for some time that additional factors also influence outcome. These include histologic grade, lymphatic or vascular invasion, mitotic index, performance status, symptoms, and most recently genetic and biochemical markers. It is the aim of this volume to compile those prognostic factors that have emerged as important determinants of outcome for tumors at various sites. This compilation represents the first phase of a more extensive process to integrate all prognostic factors in cancer to further enhance the prediction of outcome following treatment. Certain issues surround ing the assessment and reporting of prognostic factors are also considered. Importance of Prognostic Factors Prognostic factors in cancer often have an immense influence on outcome, while treatment often has a much weaker effect. For example, the influence of the presence of lymph node involvement on survival of patients with metastatic breast cancer is much greater than the effect of adjuvant treatment with tamoxifen in the same group of patients [5].
Paul Hermanek
M. K. Gospodarowicz, P. Hermanek, and D. E. Henson Attention to innovations in cancer treatment has tended to eclipse the importance of prognostic assessment. However, the recognition that prognostic factors often have a greater impact on outcome than available therapies and the proliferation of biochemical, molecular, and genetic markers have resulted in renewed interest in this field. The outcome in patients with cancer is determined by a combination of numerous factors. Presently, the most widely recognized are the extent of disease, histologic type of tumor, and treatment. It has been known for some time that additional factors also influence outcome. These include histologic grade, lymphatic or vascular invasion, mitotic index, performance status, symptoms, and most recently genetic and biochemical markers. It is the aim of this volume to compile those prognostic factors that have emerged as important determinants of outcome for tumors at various sites. This compilation represents the first phase of a more extensive process to integrate all prognostic factors in cancer to further enhance the prediction of outcome following treatment. Certain issues surround ing the assessment and reporting of prognostic factors are also considered. Importance of Prognostic Factors Prognostic factors in cancer often have an immense influence on outcome, while treatment often has a much weaker effect. For example, the influence of the presence of lymph node involvement on survival of patients with metastatic breast cancer is much greater than the effect of adjuvant treatment with tamoxifen in the same group of patients [5].
©2017 GoogleSite Terms of ServicePrivacyDevelopersArtistsAbout Google
By purchasing this item, you are transacting with Google Payments and agreeing to the Google Payments Terms of Service and Privacy Notice.